Company: ABBV
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001551152-25-000029
Chunk: 17

Company: AbbVie Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
695 shares as of March 31, 2025 and 66,337,508 as of December 31, 2024(9,137)(8,201)Additional paid-in capital21,808 21,333 Accumulated deficit(9,527)(7,900)Accumulated other comprehensive loss(1,742)(1,925)Total stockholders' equity1,420 3,325 Noncontrolling interest42 39 Total equity1,462 3,364 Total liabilities and equity$136,165 $135,161 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2025 Form 10-Q | 3

AbbVie Inc. and Subsidiaries Condensed Consolidated Statements of Equity (unaudited) 

(in millions)Common shares outstandingCommon stockTreasury stockAdditional paid-in capitalAccumulated deficitAccumulated other comprehensive lossNoncontrolling interestTotalBalance at December 31, 20231,766 $18 $(6,533)$20,180 $(1,000)$(2,305)$37 $10,397 Net earnings attributable to AbbVie Inc.— — — — 1,369 — — 1,369 Other comprehensive loss, net of tax— — — — — (149)— (149)Dividends declared— — — — (2,753)— — (2,753)Purchases of treasury stock(7)— (1,324)— — — — (1,324)Stock-based compensation plans and other7 — 28 476 — — — 504 Change in noncontrolling interest— — — — — — 3 3 Balance at March 31, 20241,766 $18 $(7,829)$20,656 $(2,384)$(2,454)$40 $8,047 Balance at December 31, 20241,765 $18 $(8,201)$21,333 $(7,900)$(1,925)$39 $3,364 Net earnings attributable to AbbVie Inc.— — — — 1,286 — — 1,286 Other comprehensive income, net of tax— — — —